{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:13Z","timestamp":1787027053132,"version":"build-2736575974"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the impact of dupilumab treatment on the quality of life, psychological factors and clinical symptoms, in patients with moderate-to-severe atopic dermatitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search was conducted in PubMed, Web of Science, Embase, and Cochrane Library. Data coverage extends until April 2024. The study exclusively encompassed randomized controlled trials. The primary outcome was the quality of life of patients, with subgroup analyses conducted. Revman 5.4 and Stata 15.1 software were used for the analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 17 studies with a total of 6,665 participants. To evaluate quality of life, six instruments were used: the Dermatology Life Quality Index (DLQI), the Quality of Life Index for Atopic Dermatitis (QoLIAD), the Children\u2019s Dermatology Life Quality Index (CDLQI), the Infant\u2019s Dermatitis Quality of Life Index (IDQoL), the Dermatitis Family Impact (DFI), and the EuroQol-5 Dimension (EQ-5D). The QoLIAD is specifically designed for atopic dermatitis. The results demonstrated that dupilumab significantly improved DLQI\/QoLIAD scores in adult patients (SMD = \u22120.64, 95% CI [-0.84, \u22120.45], p &amp;lt; 0.00001), the CDLQI\/IDQoL scores in children\/adolescents (SMD = \u22120.73, 95% CI [-0.84, \u22120.63], p &amp;lt; 0.00001), family quality of life measured by DFI (SMD = \u22120.97, 95% CI [-1.20, \u22120.75], p &amp;lt; 0.00001), and EQ-5D scores (SMD = 0.64, 95% CI [0.46, 0.82], p &amp;lt; 0.00001). The study also reported significant improvements in sleep-related metrics, total score on the Hospital Anxiety and Depression Scale (HADS), HADS anxiety scale, and HADS depression score. Additional improvements were observed in the Patient-Oriented Eczema Measure (POEM), pruritus Numeric Rating Scale (NRS), Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), percent Body Surface Area (BSA), Global Individual Sign Score (GISS), and Investigator\u2019s Global Assessment (IGA) response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study demonstrates that dupilumab significantly enhances patients\u2019 quality of life and alleviates symptoms. This meta-analysis utilizes various assessment tools to evaluate quality of life, synthesizing data from recent clinical trials. It builds on prior research to provide a comprehensive analysis of dupilumab\u2019s effects and overall efficacy. The aim of this study is to offer evidence-based insights to improve the clinical application of dupilumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1587977","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T01:22:51Z","timestamp":1749518571000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Yunqing","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingtao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","article-title":"Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry","volume":"84","author":"Ari\u00ebns","year":"2021","journal-title":"J. Am. Acad. Dermatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","article-title":"Dupilumab provides acceptable safety and sustained efficacy for up to 4 Years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"23","author":"Beck","year":"2022","journal-title":"Am. J. Clin. Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1111\/all.15432","article-title":"Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis","volume":"77","author":"Berdyshev","year":"2022","journal-title":"Allergy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jaip.2023.03.011","article-title":"Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations","volume":"11","author":"Butala","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/all.15818","article-title":"Mind and skin: exploring the links between inflammation, sleep disturbance and neurocognitive function in patients with atopic dermatitis","volume":"79","author":"Cameron","year":"2024","journal-title":"Allergy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"965133","DOI":"10.3389\/fmed.2022.965133","article-title":"Psychologic interventions in patients with the chronic dermatologic itch in atopic dermatitis and psoriasis: a step forward with family constellations seminars","volume":"9","author":"Capec","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1038\/s41598-024-55965-y","article-title":"The burden of atopic dermatitis in Portuguese patients: an observational study","volume":"14","author":"Coelho","year":"2024","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"adv13467","DOI":"10.2340\/actadv.v104.13467","article-title":"Clinically meaningful responses to dupilumab among children aged 6 Months to 5 Years with moderate-to-severe atopic dermatitis who did not achieve clear or almost clear skin according to the investigator's global assessment: a post hoc analysis of a phase 3 trial","volume":"104","author":"Cork","year":"2024","journal-title":"Acta Dermato-Venereologica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t","volume":"178","author":"de Bruin\u2010Weller","year":"2018","journal-title":"Br. J. Dermatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J. Am. Acad. Dermatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the national eczema association","volume":"137","author":"Drucker","year":"2017","journal-title":"J. Invest Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666x.2021.1940962","article-title":"The IL-4, IL-13 and IL-31 pathways in atopic dermatitis","volume":"17","author":"Dubin","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J. Am. Acad. Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/exd.13992","article-title":"What is new in the psychology of chronic itch?","volume":"28","author":"Evers","year":"2019","journal-title":"Exp. Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","article-title":"The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment","volume":"20","author":"Facheris","year":"2023","journal-title":"Cell Mol. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13555-020-00459-8","article-title":"The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in Europe: analysis of a cross-sectional survey","volume":"11","author":"Girolomoni","year":"2021","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/12034754221130969","article-title":"Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta-analysis","volume":"26","author":"Koskeridis","year":"2022","journal-title":"J. Cutan. Med. Surg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1111\/jdv.18450","article-title":"Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice","volume":"36","author":"Lasek","year":"2022","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.19580","article-title":"The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990\u20132017","volume":"184","author":"Laughter","year":"2020","journal-title":"Br. J. Dermatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","article-title":"The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use","volume":"132","author":"Lewis-Jones","year":"1995","journal-title":"Br. J. Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann. Intern Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.it.2018.10.001","article-title":"The itch-scratch cycle: a neuroimmune perspective","volume":"39","author":"Mack","year":"2018","journal-title":"Trends Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/bjd\/ljad284","article-title":"Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study","volume":"189","author":"Merola","year":"2023","journal-title":"Br. J. Dermatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e15407","DOI":"10.1111\/dth.15407","article-title":"Impact on health\u2010related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate\u2010to\u2010severe atopic dermatitis","volume":"35","author":"Miniotti","year":"2022","journal-title":"Dermatol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40257-019-00478-y","article-title":"Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial","volume":"21","author":"Paller","year":"","journal-title":"Am. J. Clin. Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s12325-023-02753-1","article-title":"Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6 Months to 5 Years with severe atopic dermatitis","volume":"41","author":"Paller","year":"2024","journal-title":"Adv. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"","journal-title":"J. Am. Acad. Dermatology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jaci.2024.04.009","article-title":"Biologic and small-molecule therapy for treating moderate to severe atopic dermatitis: mechanistic considerations","volume":"154","author":"Rothenberg-Lausell","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40257-023-00791-7","article-title":"Dupilumab provides clinically meaningful responses in children aged 6-11 Years with severe atopic dermatitis: post hoc analysis results from a phase III trial","volume":"24","author":"Siegfried","year":"2023","journal-title":"Am. J. Clin. Dermatology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"","journal-title":"J. Am. Acad. Dermatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jamadermatol.2021.4778","article-title":"Treatment outcomes associated with dupilumab use in patients with atopic dermatitis: 1-year results from the RELIEVE-AD study","volume":"158","author":"Strober","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.alit.2022.04.003","article-title":"Peripheral itch sensitization in atopic dermatitis","volume":"71","author":"Tominaga","year":"2022","journal-title":"Allergol. Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/bjd.15905","article-title":"Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial","volume":"178","author":"Tsianakas","year":"2018","journal-title":"Br. J. dermatology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"601","DOI":"10.5114\/ada.2022.117740","article-title":"Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized controlled trials","volume":"39","author":"Wu","year":"2022","journal-title":"Postepy Dermatol Alergol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/pde.13727","article-title":"The impact of pediatric atopic dermatitis on families: a review","volume":"36","author":"Yang","year":"2019","journal-title":"Pediatr. Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaad.2024.04.026","article-title":"Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay registry","volume":"91","author":"Zhang","year":"2024","journal-title":"J. Am. Acad. Dermatology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjd.20690","article-title":"The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study","volume":"186","author":"Zhao","year":"2022","journal-title":"Br. J. Dermatol"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1587977\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T01:22:52Z","timestamp":1749518572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1587977\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":51,"alternative-id":["10.3389\/fphar.2025.1587977"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1587977","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"article-number":"1587977"}}